Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Glutathione and SLU-PP-332 — mechanism, side effects, legal status, and pricing.
Glutathione is an endogenous tripeptide (gamma-L-glutamyl-L-cysteinyl-glycine) that serves as the principal intracellular antioxidant in mammalian cells. It is not FDA-approved as a drug in the US; parenteral glutathione is used off-label (and in some compounding settings) for oxidative stress, hepatic support, and — controversially — skin lightening. The FDA has warned against injectable glutathione for skin lightening (2019) due to reports of serious adverse events.
SLU-PP-332 is a small-molecule (non-peptide) pan-agonist of estrogen-related receptors ERRα/β/γ developed at Saint Louis University. Studied preclinically as an exercise mimetic in rodents, it has no human clinical data and is NOT FDA-approved. Sold only as a grey-market research chemical.
Glutathione
SLU-PP-332
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Glutathione
SLU-PP-332
COA corpus from Disclosed Labs — independently tested batches only.
Glutathione
62
COAs
99.5%
Avg purity
10
Labs
SLU-PP-332
26
COAs
99.5%
Avg purity
11
Labs
A randomized, double-blind pilot trial (Hauser et al., Movement Disorders, 2009, PMID 19230029) tested IV glutathione 1,400 mg three times weekly for 4 weeks in Parkinson's disease (n=21); it was well tolerated but did NOT show a statistically significant effect on UPDRS scores. A large randomized trial of inhaled glutathione (646 mg every 12 hours for 6 months) in cystic fibrosis (Griese et al., Am J Respir Crit Care Med, 2013, PMID 23631796) did not demonstrate clinically relevant improvements in lung function, exacerbations, or quality of life. Oral glutathione has poor bioavailability due to GI degradation, driving investigation of IV, nebulized, liposomal, and sublingual delivery. The FDA issued a 2019 warning about compounded sterile injectable glutathione made from dietary-grade ingredient, citing adverse-event reports (including Stevens-Johnson syndrome, toxic epidermal necrolysis, and kidney dysfunction) particularly in the context of unregulated IV skin-lightening use.
Key references
Billon et al. (ACS Chemical Biology, 2023) reported that SLU-PP-332 in sedentary mice increased treadmill endurance, enhanced slow-twitch fiber content, boosted mitochondrial biogenesis, and conferred resistance to high-fat-diet weight gain without exercise training. A follow-up (Billon et al., J Pharmacol Exp Ther, 2024) showed benefits in mouse metabolic-syndrome models. Developed at Saint Louis University (Burris/Walker/Elgendy groups). Rodent/preclinical data ONLY — no human clinical trials have been initiated. Not FDA-approved; not a peptide.
Key references
Glutathione (Immune) and SLU-PP-332 (Metabolic) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs